Role of Maraviroc and/or Rapamycin in Aging Liver Processes

Abstract Background: Cellular senescence and low-grade inflammation favor the acceleration of aging. The liver is an essential metabolic organ because changes related to its function are related to age-related diseases. The objective of this study was to evaluate the effects of maraviroc (MVC) and/or rapamycin (RAPA) on liver tissue in an experimental model of aging in mice.Materials and methods: Eighty male homozygous IL10KO mice were randomly assigned to one of 4 groups (n= 20): i) IL10KO group (IL10KO); ii) IL10KO mice that received MVC in drinking water (MVC group), iii) IL10KO mice that received RAPA in drinking water (RAPA group), and iv) MVC-RAPA group that received MVC and RAPA in drinking water. Liver samples were analyzed. Gene expression quantification, western blotting and histopathological analyses were also performed.Results: The proinflammatory cytokines IL-6 and IL-18 were decreased in the MVC and MVC/RAPA groups, and TNF-α was decreased in all therapeutic groups. Galactosidase beta-1, a senescence biomarker, was also significantly reduced in all therapeutic groups, as were NK-kB1 and NF-kB2. In all groups, mTOR and CCL5 were significantly reduced. CCR5 expression was decreased in the MVC and MVC/RAPA groups.Conclusions: MVC and RAPA may protect against some factors involved in liver aging. More studies will be necessary to verify their clinical applications.